文献速递瓣膜病与结构性心脏病

经导管或外科主动脉瓣膜性能对中危及以上患者5年结局的影响

Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk.
PubMed 文献 · J Am Coll Cardiol · 2025-03-09

该事后分析汇总了U.S. High Risk Pivotal、SURTAVI、Extreme Risk Pivotal和CoreValve Continued Access Study共5,606例患者,评估CoreValve/Evolut TAVR或外科术后5年生物瓣膜功能障碍(BVD)的发生率及临床结局。结果显示TAVR组BVD发生率低于外科组(9.7% vs 15.3%),且BVD与5年全因死亡、心血管死亡及瓣膜病或心衰恶化住院风险增加相关。

要点

  • CoreValve/Evolut TAVR术后5年BVD发生率低于外科(9.7% vs 15.3%)。
  • BVD与5年全因死亡、心血管死亡及心衰住院风险增加相关。
  • 中危及以上主动脉瓣狭窄患者选择TAVR或外科时需关注远期瓣膜性能。

核心结论

  • CoreValve/Evolut TAVR术后5年瓣膜性能显著优于外科手术。
  • TAVR和外科术后发生BVD均与5年临床结局恶化相关。

研究设计与样本

  • 事后分析汇总U.S. High Risk Pivotal(n=726)、SURTAVI(n=1,618)、Extreme Risk Pivotal(n=608)和CoreValve Continued Access Study(n=2,654)数据。
  • 共评估5,606例患者,其中RCT患者2,344例(TAVR 1,227例,外科1,117例),非RCT TAVR患者3,262例。
  • 主要终点为RCT患者5年内BVD发生率,并评估BVD与5年临床结局的关联。

主要发现

  • RCT患者中TAVR组BVD发生率为9.7%,外科组为15.3%(subdistribution HR: 0.57; 95% CI: 0.45-0.73; P < 0.001)。
  • 在RCT和非RCT汇总人群中,BVD与5年全因死亡风险增加相关(HR: 1.49; 95% CI: 1.32-1.68; P < 0.001)。
  • BVD与5年心血管死亡风险增加相关(HR: 1.76; 95% CI: 1.52-2.03; P < 0.001)。
  • BVD与5年瓣膜病或心衰恶化住院风险增加相关(HR: 1.48; 95% CI: 1.23-1.78; P < 0.001)。

临床怎么用

  • 对于中危及以上主动脉瓣狭窄患者,选择TAVR或外科手术时应考虑远期瓣膜功能障碍风险。
  • 术后随访中应关注BVD的发生,因其与死亡和心衰住院风险增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence and clinical importance of bioprosthetic valve dysfunction (BVD) in patients undergoing supra-annular, self-expanding transcatheter aortic valve replacement (TAVR) or surgery is not well understood. OBJECTIVES: The purpose of this study was to evaluate the 5-year incidence and clinical outcomes of BVD in patients undergoing CoreValve/Evolut TAVR or surgery. METHODS: This post hoc analysis pooled data from the U.S. High Risk Pivotal (n = 726) and SURTAVI (n = 1,618) randomized controlled trials (RCTs), the Extreme Risk Pivotal trial (n = 608), and CoreValve Continued Access Study (n = 2,654). The primary endpoint was the incidence of BVD through 5 years from the RCTs. The association of BVD with 5-year clinical outcomes was evaluated in the pooled RCT and non-RCT populations. RESULTS: Of 5,606 patients evaluated, 3,070 (54.8%) were men, and the mean age was 82.2 ± 7.4 years. A total of 2,344 RCT patients, including 1,227 who received TAVR and 1,117 who received surgery, and 3,262 non-RCT TAVR patients were included. The rate of BVD was lower in RCT patients undergoing CoreValve/Evolut TAVR compared with surgery (9.7% vs 15.3%; subdistribution HR: 0.57; 95% CI: 0.45-0.73; P < 0.001). In the pooled RCT and non-RCT cohort, BVD was associated with increased 5-year all-cause mortality (HR: 1.49; 95% CI: 1.32-1.68; P < 0.001), cardiovascular mortality (HR: 1.76; 95% CI: 1.52-2.03; P < 0.001), and hospitalization for valve disease or worsening heart failure (HR: 1.48; 95% CI: 1.23-1.78; P < 0.001). CONCLUSIONS: Five-year valve performance was significantly better after CoreValve/Evolut TAVR compared with surgery. Development of BVD in TAVR and surgery patients was associated with worsened 5-year clinical outcomes. (Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement, NCT01240902; Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement [SURTAVI], NCT01586910; Safety and Efficacy Continued Access Study of the Medtronic CoreValve System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement, NCT01531374).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Yakubov SJ, Van Mieghem NM, Oh JK, et al. Impact of Transcatheter or Surgical Aortic Valve Performance on 5-Year Outcomes in Patients at ≥ Intermediate Risk. J Am Coll Cardiol. 2025. PMID: 40175015. doi:10.1016/j.jacc.2025.02.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。